BLCM — Bellicum Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $0.95m
- -$4.96m
- $1.50m
- 14
- 70
- 20
- 26
Annual cashflow statement for Bellicum Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -98 | -112 | -7.72 | -9.71 | -25 |
| Depreciation | |||||
| Non-Cash Items | 14.5 | 34.6 | -42.2 | -11.2 | 0.645 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.02 | -6.9 | -8.16 | -2.35 | -1.47 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -74.8 | -77.6 | -56.6 | -23.1 | -25.8 |
| Capital Expenditures | -1.62 | -0.522 | -0.625 | -0.007 | -0.021 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 12 | 49.4 | 14.7 | 0.9 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 10.4 | 48.9 | 14.1 | 0.893 | -0.021 |
| Financing Cash Flow Items | -0.195 | 11.2 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 68.1 | 74.1 | -14.2 | 32.9 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.64 | 45.1 | -56.8 | 10.7 | -25.8 |